Bionano Genomics, Inc. — Director's Dealing 2018

Aug 27, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioNano Genomics, Inc (BNGO)
CIK: 0001411690
Period of Report: 2018-08-23

Reporting Person: LC Fund VI, L.P. (10% Owner)
Reporting Person: LC Parallel Fund VI, L.P. (10% Owner)
Reporting Person: Rosy Shine Ltd (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-23	Common Stock	C	199653	—	Acquired	199653	Indirect
2018-08-23	Common Stock	C	150550	—	Acquired	350203	Indirect
2018-08-23	Common Stock	C	637984	—	Acquired	988187	Indirect
2018-08-23	Common Stock	C	784728	—	Acquired	1772915	Indirect
2018-08-23	Common Stock	C	1134000	—	Acquired	2906915	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-23	Series C Convertible Preferred Stock	$	C	8545184	Disposed		Common Stock (199653)	Indirect
2018-08-23	Series D Convertible Preferred Stock	$	C	6443565	Disposed		Common Stock (150550)	Indirect
2018-08-23	Series D-1 Convertible Preferred Stock	$	C	27305708	Disposed		Common Stock (637984)	Indirect

Footnotes

F1: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date.

F2: The shares are held as follows: 191,667 shares held by LC Fund VI, L.P. ("LC Fund") and 7,986 shares held by LC Parallel Fund VI, L.P.
("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.

F3: The shares are held as follows: 143,533 shares held by LC Fund and 7,017 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company.

F4: The shares are held as follows: 91,700 shares held by LC Fund, 540,631 shares held by Parallel Fund and 5,653 shares held by LC
Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital, a
limited liability Chinese company ("Legend Capital"). The Reporting Person is ultimately controlled and managed by Legend Capital.

F5: Represents the conversion of an outstanding convertible promissory note in the principal amount of $3,460,000, plus $144,846.03 accrued
interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $6.125 per share.

F6: Represents the conversion of an outstanding convertible promissory note in the principal amount of $5,000,000, plus $209,315.07 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $6.125 per share.

F7: Rosy Shine Limited is ultimately controlled and managed by Legend Holdings, a limited liability Chinese joint stock company listed on a Stock Exchange of Hong Kong (3396), which is controlled by its board of directors. The board of directors of Legend Holdings has sole voting and investment power over the shares held by Rosy Shine Limited. None of the members of the board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares.